Detail akcie Tempus AI Rg-A online

Business Summary: Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Tempus AI Inc revenues increased 84% to $904.6M. Net loss applicable to common stockholders decreased 74% to $190.9M. Revenues reflect Genomics increase from $331.3M to $688.5M, Data and services increase of 34% to $216.1M. Lower net loss reflects Biotechnology and Medical research segment loss decrease of 70% to $191.5M.